COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00504296
Recruitment Status : Completed
First Posted : July 19, 2007
Last Update Posted : April 8, 2020
Information provided by (Responsible Party):
Canadian Cancer Trials Group ( NCIC Clinical Trials Group )

Brief Summary:

RATIONALE: SB939 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase I trial is studying the side effects and best dose of SB939 in treating patients with locally advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: HDAC inhibitor SB939 Other: immunoenzyme technique Other: immunohistochemistry staining method Other: immunologic technique Other: laboratory biomarker analysis Other: liquid chromatography Other: mass spectrometry Other: pharmacological study Phase 1

Detailed Description:



  • To determine the recommended phase II dose of oral SB939 in patients with solid tumors.


  • To determine the toxic effects of SB939 and its association with dose and pharmacokinetics.
  • To assess the pharmacokinetic profile of SB939.
  • To assess preliminary evidence of antitumor effects of SB939 in patients with measurable disease as documented by objective response.
  • To establish proof-of-principle for SB939 effects on histone acetylation by evaluation of histone acetylation and other biomarkers in peripheral blood mononuclear cells (PBMCs) at all dose levels.

OUTLINE: Patients receive oral SB939 once daily on days 1-5 and 15-19. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.

Patients undergo blood sample collection periodically during course 1 for pharmacokinetic and pharmacodynamic studies. Samples are analyzed for levels of SB939 via LC-MS/MS method and levels of acetylated histone 3 (AcH3), target effect, downstream consequences, and tumor response via western blot, immunohistochemistry, or ELISA methods.

After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 39 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Clinical and Pharmacokinetic Study of SB939 in Patients With Advanced Cancer
Actual Study Start Date : June 21, 2007
Actual Primary Completion Date : April 22, 2010
Actual Study Completion Date : June 21, 2011

Arm Intervention/treatment
Experimental: SB939 Drug: HDAC inhibitor SB939
SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.

Other: immunoenzyme technique
Other: immunohistochemistry staining method
Other: immunologic technique
Other: laboratory biomarker analysis
Other: liquid chromatography
Other: mass spectrometry
Other: pharmacological study

Primary Outcome Measures :
  1. Recommended phase II dose [ Time Frame: Each dose level ]
    Assess for safety, tolerability, toxicity profile and dose limiting toxicities

Secondary Outcome Measures :
  1. Safety [ Time Frame: Each dose level ]
    Safety, tolerability, toxicity profile, dose limiting toxicities of SB939.

  2. Pharmacokinetic profile [ Time Frame: Cycle 1 day 1 and 15 ]
    Samples collected over multiple timepoints

  3. SB939 effects on histone H3 acetylation [ Time Frame: Cycle 1 days 1 and 15 ]
    Levels of AcH3 will be determined using wetern Blot, immunohistochemistry or Elisa method.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


Inclusion criteria:

  • Histologically or cytologically confirmed locally advanced or metastatic solid tumor

    • Refractory to standard therapy or for which conventional therapy is not reliably effective

Exclusion criteria:

  • Patients with documented CNS metastases


Inclusion criteria:

  • ECOG performance status of 0, 1, or 2
  • Must have a life expectancy of ≥ 12 weeks
  • Granulocytes (AGC) ≥ 1.5 x 10^9/L
  • Platelets ≥ 100 x 10^9/L
  • Bilirubin ≤ upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 x ULN (< 5 x ULN if liver metastases are present)
  • Serum creatinine ≤ 1.2 x ULN OR creatinine clearance ≥ 60 mL/min
  • QTc ≤ 450 msec
  • LVEF ≥ 50% by ECHO or MUGA
  • Troponin I or T ≤ ULN
  • Must be within 1½ hour's driving distance

Exclusion criteria:

  • Pathologic cardiac arrhythmia requiring active treatment

    • Patients with a history of arrhythmia must be > 12 months since last treatment with no recurrence of arrhythmia in the interval
  • Inability to take oral medication

    • Patients must be able to swallow SB939 capsules and have no gastrointestinal abnormalities (e.g., bowel obstruction or previous gastric resection) which would lead to inadequate absorption of SB939
  • Pregnant or lactating women

    • Urine or serum B-HCG must be negative
  • Women or men of child-bearing potential unless using effective contraception
  • Presence of any clinically significant co-morbidities (i.e., pulmonary disease, active CNS disease, or active infection)
  • Presence of any other significant CNS disorder that would hamper the patient's compliance
  • Presence of any significant psychiatric disorder that would hamper the patient's compliance
  • Other acute or chronic medical condition, psychiatric condition, or laboratory abnormality that may increase the risks associated with study participation/study drug administration or may interfere with the interpretation of study results
  • Pre-existing peripheral neuropathy ≥ grade 2
  • Known HIV or hepatitis B or C infection


Inclusion criteria:

  • Previous anticancer treatment must be discontinued at least 28 days prior to the first dose of study treatment (42 days [6 weeks] for nitrosoureas or mitomycin C)
  • At least 28 days since prior radiation therapy restricted to ≤ 30% of the bone marrow and recovered from toxic effects

    • Exceptions may be made for low-dose nonmyelosuppressive radiotherapy
  • Must be ≥ 14 days since any major surgery
  • Pre-existing bisphosphonate or luteinizing hormone-releasing hormone (LHRH) analog therapy (for men with hormone refractory prostate cancer) may be continued during study participation

Exclusion criteria:

  • Previous treatment with a histone deacetylase (HDAC) inhibitor
  • Treatment with another investigational therapy within 28 days prior to study entry
  • Other concurrent anticancer treatment or investigational therapy
  • Concurrent agents with a known risk of Torsade de Pointes
  • Concurrent G-CSF, GM-CSF, or other hematopoietic growth factors may not be used as a substitute for a scheduled dose reduction (may be used in the management of acute toxicity)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00504296

Layout table for location information
Canada, Ontario
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
Sponsors and Collaborators
NCIC Clinical Trials Group
Layout table for investigator information
Study Chair: Lillian L. Siu, MD, FRCPC Princess Margaret Hospital, Canada
Publications of Results:
Layout table for additonal information
Responsible Party: NCIC Clinical Trials Group Identifier: NCT00504296    
Other Study ID Numbers: I188
CAN-NCIC-IND188 ( Registry Identifier: NCI US - Physician Data Query )
S*BIO-SB939-2007-002 ( Other Identifier: S*BIO )
CDR0000558934 ( Other Identifier: PDQ )
First Posted: July 19, 2007    Key Record Dates
Last Update Posted: April 8, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Canadian Cancer Trials Group ( NCIC Clinical Trials Group ):
unspecified adult solid tumor, protocol specific
Additional relevant MeSH terms:
Layout table for MeSH terms
Histone Deacetylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action